TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI (Ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
PDF Version NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Peering Into TG Therapeutics's Recent Short Interest
TG Therapeutics's (NYSE:TGTX) short percent of float has fallen 6.31% since its last report. The company recently reported that it has 35.71 million shares sold short, which is 25.55% of all regular s
TG Therapeutics Under Pressure: Navigating the Perils of Government Contracts and Compliance Hurdles
TG Therapeutics | 10-Q: Quarterly report
New Forecasts: Here's What Analysts Think The Future Holds For TG Therapeutics, Inc. (NASDAQ:TGTX)
Shareholders in TG Therapeutics, Inc. (NASDAQ:TGTX) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased their
Earnings Call Summary | TG Therapeutics(TGTX.US) Q1 2024 Earnings Conference
The following is a summary of the TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript:Financial Performance:TG Therapeutics reported total revenue for Q1 2024 of $63.5 million, with U.S. Bri
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript
Rainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More Optimistic
Why TG Therapeutics Stock Was Rocketing Higher This Week
TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript
TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript
TG Therapeutics Price Target Raised to $49.00/Share From $45.00 by HC Wainwright & Co.
TG Therapeutics Price Target Raised to $49.00/Share From $45.00 by HC Wainwright & Co.
TG Therapeutics Is Maintained at Buy by Ladenburg Thalmann
TG Therapeutics Is Maintained at Buy by Ladenburg Thalmann
Express News | Ladenburg Thalmann Maintains Buy on TG Therapeutics, Raises Price Target to $40
TG Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 147.83% Ladenburg Thalmann $39 → $40 Maintains Buy 04/18/2024 178.81% HC Wainwright & Co. → $45
TG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Express News | TG Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $49 From $45
Sell Rating on TG Therapeutics: Caution Amid Competitive Threats and Decelerating Prescription Growth
Express News | TG Therapeutics Inc : Jefferies Raises Target Price to $44 From $40
Q1 2024 TG Therapeutics Inc Earnings Call
No Data